The cancer drug acalabrutinib reduced respiratory distress in COVID-19 patients


Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein provided clinical benefit to a small group of patients with severe COVID-19.

Researchers observed that the off-label use of the cancer drug acalabrutinib, a BTK inhibitor that is approved to treat several blood cancers, was associated with reduced respiratory distress and a reduction in the overactive immune response in most of the treated patients.

The findings were published June 5, 2020, in Science Immunology. The study was led by researchers in the Center for Cancer Research at the National Cancer Institute (NCI), in collaboration with researchers from the National Institute of Allergy and Infectious Diseases (NIAID), both part of the National Institutes of Health (NIH), as well as the U.S. Department of Defense’s Walter Reed National Military Medical Center, and four other hospitals nationally.

These findings should not be considered clinical advice but are being shared to assist the public health response to COVID-19. While BTK inhibitors are approved to treat certain cancers, they are not approved as a treatment for COVID-19.

This strategy must be tested in a randomized, controlled clinical trial in order to understand the best and safest treatment options for patients with severe COVID-19.

The BTK protein plays an important role in the normal immune system, including in macrophages, a type of innate immune cell that can cause inflammation by producing proteins known as cytokines. Cytokines act as chemical messengers that help to stimulate and direct the immune response. In some patients with severe COVID-19, a large amount of cytokines are released in the body all at once, causing the immune system to damage the function of organs such as the lungs, in addition to attacking the infection.

This dangerous hyperinflammatory state is known as a “cytokine storm.” At present, there are no proven treatment strategies for this phase of the illness. The study was developed to test whether blocking the BTK protein with acalabrutinib would reduce inflammation and improve the clinical outcome for hospitalized patients with severe COVID-19.

This prospective off-label clinical study included 19 patients with a confirmed COVID-19 diagnosis that required hospitalization, as well as with low blood-oxygen levels and evidence of inflammation.

Of these patients, 11 had been receiving supplemental oxygen for a median of two days, and eight others had been on ventilators for a median of 1.5 (range 1-22) days.

Within one to three days after they began receiving acalabrutinib, the majority of patients in the supplemental oxygen group experienced a substantial drop in inflammation, and their breathing improved.

Eight of these 11 patients were able to come off supplemental oxygen and were discharged from the hospital. Although the benefit of acalabrutinib was less dramatic in patients on ventilators, four of the eight patients were able to come off the ventilator, two of whom were eventually discharged.

The authors note that the ventilator patient group was extremely clinically diverse and included patients who had been on a ventilator for prolonged periods of time and had major organ dysfunction. Two of the patients in this group died.

Blood samples from patients in the study showed that levels of interleukin-6 (IL-6), a major cytokine associated with hyperinflammation in severe COVID-19, decreased after treatment with acalabrutinib.

Counts of lymphocytes, a type of white blood cell, also rapidly improved in most patients. A low lymphocyte count has been associated with worse outcome for patients with severe COVID-19.

The researchers also tested blood cells from patients with severe COVID-19 who were not in the study. In comparison with samples from healthy volunteers, they found that these patients with severe COVID-19 had higher activity of the BTK protein and greater production of IL-6.

These findings suggest that acalabrutinib may have been effective because its target, BTK, is hyperactive in severe COVID-19 immune cells.

Acalabrutinib is a small molecule inhibitor of Bruton tyrosine kinase (BTK). By blocking BTK, acalabrutinib is designed to help slow or stop the growth of new cancer cells. Acalabrutinib is a type of targeted therapy.

Bruton Tyrosine Kinase Inhibitor
Acalabrutinib (Calquence) is a next-generation, highly selective Bruton tyrosine kinase inhibitor (BTKi) used to treat mantle cell lymphoma and CLL, now being tested for use in COVID-19 patients.

The Bruton’s tyrosine kinase pathway has a role in the production of inflammatory cytokines [Bruton tyrosine kinase inhibitor. [cited 2020 Apr 14]; available from:], and early clinical findings showed that acalabrutinib may ameliorate the severity of respiratory distress caused by COVID-19 infection through inflammation control.

The CALAVI trial will be initiated as a randomized global clinical trial to assess the potential of acalabrutinib in the treatment of the cytokine storm associated with severely ill COVID-19 patients [ AstraZeneca. AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19. [cited 2020 Apr 14]; available from:].

Additionally, other trials are being considered with different BTKi, specifically ibrutinib, to reduce the inflammatory response [EXCLUSIVE: AstraZeneca’s Calquence shows early promise For COVID-19 patients. [cited 2020 Apr 14]; available from:].

More information: M. Roschewski el al., “Inhibition of Bruton Tyrosine Kinase in Patients with Severe COVID-19,” Science Immunology (2020). … 6/sciimmunol.abd0110


Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.